{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:30:23Z","timestamp":1793046623432,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"4","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s40121-015-0092-8","type":"journal-article","created":{"date-parts":[[2015,10,5]],"date-time":"2015-10-05T09:28:34Z","timestamp":1444037314000},"page":"433-458","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database"],"prefix":"10.1007","volume":"4","author":[{"given":"Dmitri","family":"Iarikov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Wassel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Farley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumathi","family":"Nambiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,5]]},"reference":[{"key":"92_CR1","unstructured":"MONUROL\u00ae (fosfomycin tromethamine) SACHET. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/050717s007lbl.pdf . Accessed March 7, 2011."},{"issue":"11","key":"92_CR2","doi-asserted-by":"crossref","first-page":"e732","DOI":"10.1016\/j.ijid.2011.07.007","volume":"15","author":"AS Michalopoulos","year":"2011","unstructured":"Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis. 2011;15(11):e732\u20139.","journal-title":"Int J Infect Dis."},{"issue":"1","key":"92_CR3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(09)70325-1","volume":"10","author":"ME Falagas","year":"2010","unstructured":"Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis. 2010;10(1):43\u201350.","journal-title":"Lancet Infect Dis."},{"issue":"6","key":"92_CR4","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2217\/fmb.10.47","volume":"5","author":"G Samonis","year":"2010","unstructured":"Samonis G, Maraki S, Rafailidis PI, Kapaskelis A, Kastoris AC, Falagas ME. Antimicrobial susceptibility of Gram-negative nonurinary bacteria to fosfomycin and other antimicrobials. Future Microbiol. 2010;5(6):961\u201370.","journal-title":"Future Microbiol."},{"issue":"3","key":"92_CR5","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1128\/AAC.02048-13","volume":"58","author":"LV Perdig\u00e3o-Neto","year":"2014","unstructured":"Perdig\u00e3o-Neto LV, Oliveira MS, Rizek CF, Carrilho CM, Costa SF, Levin AS. Susceptibility of multiresistant gram-negative bacteria to fosfomycin and performance of different susceptibility testing methods. Antimicrob Agents Chemother. 2014;58(3):1763\u20137","journal-title":"Antimicrob Agents Chemother."},{"issue":"7","key":"92_CR6","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1086\/527442","volume":"46","author":"ME Falagas","year":"2008","unstructured":"Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis. 2008;46(7):1069\u201377.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"92_CR7","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","volume":"25","author":"A Szarfman","year":"2002","unstructured":"Szarfman A, Machado SG, O\u2019Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database. Drug Saf. 2002;25(6):381\u201392.","journal-title":"Drug Saf"},{"key":"92_CR8","unstructured":"Medical Dictionary for Regulatory Activities Maintenance and Support Services Organization [online]. http:\/\/www.meddramsso.com\/ . Accessed March 7, 2011."},{"key":"92_CR9","unstructured":"Reporting adverse drug reactions, Definitions of Terms and Criteria for their Use. Council for International Organizations of Medical Sciences (CIOMS). 2000."},{"issue":"3","key":"92_CR10","first-page":"223","volume":"156","author":"M Nohr","year":"1990","unstructured":"Nohr M, Andersen JC, Juul-Jensen KE. Prophylactic single-dose fosfomycin and metronidazole compared with neomycin, bacitracin, metronidazole and ampicillin in elective colorectal operations. Acta Chir Scand. 1990;156(3):223\u201330.","journal-title":"Acta Chir Scand."},{"issue":"6","key":"92_CR11","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/adc.88.6.512","volume":"88","author":"N Corti","year":"2003","unstructured":"Corti N, Sennhauser FH, Stauffer UG, Nadal D. Fosfomycin for the initial treatment of acute haematogenous osteomyelitis. Arch Dis Child. 2003;88(6):512\u20136.","journal-title":"Arch Dis Child"},{"issue":"5","key":"92_CR12","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/BF01644272","volume":"14","author":"LR Nissen","year":"1986","unstructured":"Nissen LR, Jacobsen J, Ravn TJ, Wahlgreen C, Auning-Hansen H. Fosfomycin-ampicillin versus gentamicin-ampicillin in the treatment of critically ill patients with pneumonia. Infection. 1986;14(5):246\u20139.","journal-title":"Infection"},{"issue":"5","key":"92_CR13","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s10156-007-0544-5","volume":"13","author":"K Ishizaka","year":"2007","unstructured":"Ishizaka K, Kobayashi S, Machida T, Yoshida K. Randomized prospective comparison of fosfomycin and cefotiam for prevention of postoperative infection following urological surgery. J Infect Chemother. 2007;13(5):324\u201331.","journal-title":"J Infect Chemother."},{"issue":"Suppl 9","key":"92_CR14","first-page":"S6","volume":"95","author":"K Chareancholvanich","year":"2012","unstructured":"Chareancholvanich K, Udomkiat P, Waikakul S. A randomized control trial between fosfomycin and cefuroxime as the antibiotic prophylaxis in knee arthroplasty. J Med Assoc Thai. 2012;95(Suppl 9):S6\u201313.","journal-title":"J Med Assoc Thai"},{"issue":"3","key":"92_CR15","first-page":"181","volume":"158","author":"L Andaker","year":"1992","unstructured":"Andaker L, Burman LG, Eklund A, et al. Fosfomycin\/metronidazole compared with doxycycline\/metronidazole for the prophylaxis of infection after elective colorectal surgery. A randomised double-blind multicentre trial in 517 patients. Eur J Surg. 1992;158(3):181\u20135.","journal-title":"Eur J Surg"},{"issue":"4","key":"92_CR16","first-page":"277","volume":"147","author":"J Lindhagen","year":"1981","unstructured":"Lindhagen J, Hadziomerovic A, Nordlung S, Zbornik J. Comparison of systemic prophylaxis with metronidazole-fosfomycin and metronidazole-cephalothin in elective colorectal surgery. Acta Chir Scand. 1981;147(4):277\u201383.","journal-title":"Acta Chir Scand."},{"issue":"9","key":"92_CR17","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1128\/AAC.02435-13","volume":"58","author":"R Sirijatuphat","year":"2014","unstructured":"Sirijatuphat R, Thamlikitkul V. Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother. 2014;58(9):5598\u2013601.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"92_CR18","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1007\/BF01644232","volume":"13","author":"H Portier","year":"1985","unstructured":"Portier H, Kazmierczak A, Lucht F, Tremeaux JC, Chavanet P, Duez JM. Cefotaxime in combination with other antibiotics for the treatment of severe methicillin-resistant staphylococcal infections. Infection. 1985;13(Suppl 1):S123\u20138.","journal-title":"Infection"},{"issue":"1","key":"92_CR19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1569-1993(02)00143-1","volume":"2","author":"A Mirakhur","year":"2003","unstructured":"Mirakhur A, Gallagher MJ, Ledson MJ, Hart CA, Walshaw MJ. Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis. J Cyst Fibros. 2003;2(1):19\u201324.","journal-title":"J Cyst Fibros"},{"issue":"3","key":"92_CR20","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/BF01644014","volume":"17","author":"A Meissner","year":"1989","unstructured":"Meissner A, Haag R, Rahmanzadeh R. Adjuvant fosfomycin medication in chronic osteomyelitis. Infection. 1989;17(3):146\u201351.","journal-title":"Infection"},{"issue":"5","key":"92_CR21","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1179\/joc.2005.17.5.527","volume":"17","author":"D Stengel","year":"2005","unstructured":"Stengel D, Gorzer E, Schintler M, et al. Second-line treatment of limb-threatening diabetic foot infections with intravenous fosfomycin. J Chemother. 2005;17(5):527\u201335.","journal-title":"J Chemother"},{"issue":"2","key":"92_CR22","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1469-0691.2009.02921.x","volume":"16","author":"A Michalopoulos","year":"2010","unstructured":"Michalopoulos A, Virtzili S, Rafailidis P, Chalevelakis G, Damala M, Falagas ME. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect. 2010;16(2):184\u20136.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"92_CR23","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijantimicag.2010.09.002","volume":"37","author":"A Florent","year":"2011","unstructured":"Florent A, Chichmanian RM, Cua E, Pulcini C. Adverse events associated with intravenous fosfomycin. Int J Antimicrob Agents. 2011;37(1):82\u20133.","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl 1","key":"92_CR24","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1159\/000222076","volume":"23","author":"R Hutzler","year":"1977","unstructured":"Hutzler R, Fernandes V, Munoz D, Rozentraub A. Activity of fosfomycin in the treatment of bacterial infections. Chemotherapy. 1977;23(Suppl 1):358\u201364.","journal-title":"Chemotherapy."},{"issue":"Suppl 1","key":"92_CR25","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1159\/000222069","volume":"23","author":"J Llorens","year":"1977","unstructured":"Llorens J, Ley G, Fores A, Olay T. Acute infantile pneumonopathies treated with fosfomycin. Chemotherapy. 1977;23(Suppl 1):315\u201323.","journal-title":"Chemotherapy."},{"key":"92_CR26","doi-asserted-by":"crossref","unstructured":"Hernandez Casado V. Fosfomycin in a traumatological department. Chemotherapy. 1977;23(Suppl 1):403\u201310.","DOI":"10.1159\/000222082"},{"issue":"Suppl 1","key":"92_CR27","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1159\/000222075","volume":"23","author":"A Menendez","year":"1977","unstructured":"Menendez A, Tutor A, Sousa AS. Treatment of respiratory infections with fosfomycin. Chemotherapy. 1977;23(Suppl 1):348\u201357.","journal-title":"Chemotherapy."},{"issue":"Suppl 1","key":"92_CR28","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1159\/000222080","volume":"23","author":"A Gallardo","year":"1977","unstructured":"Gallardo A, Saez JM, Enriquez G, et al. Surgical suppurating infections and surgical abdominal infections treated with fosfomycin. Chemotherapy. 1977;23(Suppl 1):392\u20138.","journal-title":"Chemotherapy."},{"issue":"Suppl 1","key":"92_CR29","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1159\/000222084","volume":"23","author":"F Baquero","year":"1977","unstructured":"Baquero F, Hortelano JG, Navarro M, et al. Antibiotherapy of Serratia marcescens septicemia in children. Chemotherapy. 1977;23(Suppl 1):416\u201322.","journal-title":"Chemotherapy."},{"key":"92_CR30","doi-asserted-by":"crossref","unstructured":"Ruiz Garcia A, de la Lastra AM, Garzon JM, Reig M, Rodriguez A. Fosfomycin in puerperal infections and its elimination in lochia. Chemotherapy. 1977;23(Suppl 1):281\u20136.","DOI":"10.1159\/000222061"},{"issue":"1","key":"92_CR31","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ijantimicag.2013.09.010","volume":"43","author":"K Pontikis","year":"2014","unstructured":"Pontikis K, Karaiskos I, Bastani S, et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents. 2014;43(1):52\u20139.","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"92_CR32","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/cid\/ciu580","volume":"59","author":"A Rio del","year":"2014","unstructured":"del Rio A, Gasch O, Moreno A, et al. Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: a multicenter clinical trial. Clin Infect Dis. 2014;59(8):1105\u201312.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"92_CR33","first-page":"420","volume":"55","author":"N Rudenko","year":"2005","unstructured":"Rudenko N, Dorofeyev A. Prevention of recurrent lower urinary tract infections by long-term administration of fosfomycin trometamol. Double blind, randomized, parallel group, placebo controlled study. Arzneimittelforschung. 2005;55(7):420\u20137.","journal-title":"Arzneimittelforschung"},{"key":"92_CR34","doi-asserted-by":"crossref","unstructured":"Costantini E, Zucchi A, Salvini E, et al. Prulifloxacin vs fosfomycin for prophylaxis in female patients with recurrent UTIs: a non-inferiority trial. Int Urogynecol J. 2014;25(9):1173\u20138.","DOI":"10.1007\/s00192-013-2318-1"},{"key":"92_CR35","doi-asserted-by":"crossref","unstructured":"Naber KG, Thyroff-Friesinger U. Fosfomycin trometamol versus ofloxacin\/co-trimoxazole as single dose therapy of acute uncomplicated urinary tract infection in females: a multicentre study. Infection. 1990;18(Suppl 2):S70\u20136.","DOI":"10.1007\/BF01643431"},{"issue":"Suppl 1","key":"92_CR36","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000238818","volume":"36","author":"S Zinner","year":"1990","unstructured":"Zinner S. Fosfomycin trometamol versus pipemidic acid in the treatment of bacteriuria in pregnancy. Chemotherapy. 1990;36(Suppl 1):50\u20132.","journal-title":"Chemotherapy."},{"issue":"Suppl 2","key":"92_CR37","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1007\/BF01643433","volume":"18","author":"JB Boerema","year":"1990","unstructured":"Boerema JB, Willems FT. Fosfomycin trometamol in a single dose versus norfloxacin for seven days in the treatment of uncomplicated urinary infections in general practice. Infection. 1990;18(Suppl 2):S80\u20138.","journal-title":"Infection"},{"issue":"2","key":"92_CR38","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF01641417","volume":"18","author":"J Cooper","year":"1990","unstructured":"Cooper J, Raeburn A, Brumfitt W, Hamilton-Miller JM. Single dose and conventional treatment for acute bacterial and non-bacterial dysuria and frequency in general practice. Infection. 1990;18(2):65\u20139.","journal-title":"Infection"},{"issue":"Suppl 1","key":"92_CR39","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000238813","volume":"36","author":"FP Selvaggi","year":"1990","unstructured":"Selvaggi FP, Ditonno P, Traficante A, Battaglia M, Di Lorenzo V. Fosfomycin trometamol (Monuril) versus norfloxacin in single dose for adult female uncomplicated UTIs. Multicenter randomized, double-blind study. Chemotherapy. 1990;36(Suppl 1):31\u20133.","journal-title":"Chemotherapy."},{"issue":"Suppl 1","key":"92_CR40","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000238815","volume":"36","author":"P Crocchiolo","year":"1990","unstructured":"Crocchiolo P. Single-dose fosfomycin trometamol versus multiple-dose cotrimoxazole in the treatment of lower urinary tract infections in general practice. Multicenter Group of General Practitioners. Chemotherapy. 1990;36(Suppl 1):37\u201340.","journal-title":"Chemotherapy."},{"issue":"Suppl 2","key":"92_CR41","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1007\/BF01643437","volume":"18","author":"L Baert","year":"1990","unstructured":"Baert L, Billiet I, Vandepitte J. Prophylactic chemotherapy with fosfomycin trometamol versus placebo during transurethral prostatic resection. Infection. 1990;18(Suppl 2):S103\u20136.","journal-title":"Infection"},{"issue":"Suppl 2","key":"92_CR42","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1007\/BF01643432","volume":"18","author":"J Reynaert","year":"1990","unstructured":"Reynaert J, Van Eyck D, Vandepitte J. Single dose fosfomycin trometamol versus multiple dose norfloxacin over three days for uncomplicated UTI in general practice. Infection. 1990;18(Suppl 2):S77\u20139.","journal-title":"Infection"},{"issue":"Suppl 1","key":"92_CR43","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000238817","volume":"36","author":"G Ferraro","year":"1990","unstructured":"Ferraro G, Ambrosi G, Bucci L, Palmieri R, Palmieri G. Fosfomycin trometamol versus norfloxacin in the treatment of uncomplicated lower urinary tract infections of the elderly. Chemotherapy. 1990;36(Suppl 1):46\u20139.","journal-title":"Chemotherapy."},{"issue":"Suppl 1","key":"92_CR44","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000238816","volume":"36","author":"N Principi","year":"1990","unstructured":"Principi N, Corda R, Bassetti D, Varese LA, Peratoner L. Fosfomycin trometamol versus netilmicin in children\u2019s lower urinary tract infections. Chemotherapy. 1990;36(Suppl 1):41\u20135.","journal-title":"Chemotherapy."},{"issue":"2","key":"92_CR45","first-page":"55","volume":"11","author":"S Caramalli","year":"1991","unstructured":"Caramalli S, Amprimo MC, Cavalli G, et al. Effect and pharmacokinetics of netilmicin given as bolus intramuscular administration: an open comparative trial versus amikacin and fosfomycin in elderly patients affected by urinary tract infections. Int J Clin Pharmacol Res. 1991;11(2):55\u201365.","journal-title":"Int J Clin Pharmacol Res"},{"issue":"4","key":"92_CR46","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000282164","volume":"46","author":"Z Jong de","year":"1991","unstructured":"de Jong Z, Pontonnier F, Plante P. Single-dose fosfomycin trometamol (Monuril) versus multiple-dose norfloxacin: results of a multicenter study in females with uncomplicated lower urinary tract infections. Urol Int. 1991;46(4):344\u20138.","journal-title":"Urol Int"},{"issue":"6","key":"92_CR47","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF01871127","volume":"15","author":"E Pienbroek Van","year":"1993","unstructured":"Van Pienbroek E, Hermans J, Kaptein AA, Mulder JD. Fosfomycin trometamol in a single dose versus seven days nitrofurantoin in the treatment of acute uncomplicated urinary tract infections in women. Pharm World Sci. 1993;15(6):257\u201362.","journal-title":"Pharm World Sci"},{"issue":"11","key":"92_CR48","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1128\/AAC.38.11.2612","volume":"38","author":"G Elhanan","year":"1994","unstructured":"Elhanan G, Tabenkin H, Yahalom R, Raz R. Single-dose fosfomycin trometamol versus 5-day cephalexin regimen for treatment of uncomplicated lower urinary tract infections in women. Antimicrob Agents Chemother. 1994;38(11):2612\u20134.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"92_CR49","first-page":"290","volume":"6","author":"P Careddu","year":"1987","unstructured":"Careddu P, Borzani M, Scotti L, Varotto F, Garlaschi L, Fontana P. Treatment of lower urinary tract infections in children: single dose fosfomycin trometamol versus pipemidic acid. Chemioterapia. 1987;6(4):290\u20134.","journal-title":"Chemioterapia."},{"issue":"Suppl 1","key":"92_CR50","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000472876","volume":"13","author":"LA Varese","year":"1987","unstructured":"Varese LA. Trometamol salt of fosfomycin versus netilmicin: randomized multicenter study in children\u2019s lower urinary tract infections. Eur Urol. 1987;13(Suppl 1):119\u201321.","journal-title":"Eur Urol"},{"issue":"5","key":"92_CR51","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00192-006-0190-y","volume":"18","author":"O Bayrak","year":"2007","unstructured":"Bayrak O, Cimentepe E, Inegol I, et al. Is single-dose fosfomycin trometamol a good alternative for asymptomatic bacteriuria in the second trimesterof pregnancy? Int Urogynecol J Pelvic Floor Dysfunct. 2007;18(5):525\u20139.","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct."},{"issue":"12","key":"92_CR52","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s10096-009-0805-6","volume":"28","author":"A Estebanez","year":"2009","unstructured":"Estebanez A, Pascual R, Gil V, Ortiz F, Santibanez M, Perez Barba C. Fosfomycin in a single dose versus a 7-day course of amoxicillin\u2013clavulanate for the treatment of asymptomatic bacteriuria during pregnancy. Eur J Clin Microbiol Infect Dis. 2009;28(12):1457\u201364.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"6","key":"92_CR53","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s10156-010-0079-z","volume":"16","author":"N Ceran","year":"2010","unstructured":"Ceran N, Mert D, Kocdogan FY, et al. A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections. J Infect Chemother. 2010;16(6):424\u201330.","journal-title":"J Infect Chemother."},{"issue":"3","key":"92_CR54","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ijgo.2011.03.014","volume":"114","author":"TA Usta","year":"2011","unstructured":"Usta TA, Dogan O, Ates U, Yucel B, Onar Z, Kaya E. Comparison of single-dose and multiple-dose antibiotics for lower urinary tract infection in pregnancy. Int J Gynaecol Obstet. 2011;114(3):229\u201333.","journal-title":"Int J Gynaecol Obstet"},{"issue":"Suppl 2","key":"92_CR55","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1007\/BF01643434","volume":"18","author":"A Jardin","year":"1990","unstructured":"Jardin A. A general practitioner multicenter study: fosfomycin trometamol single dose versus pipemidic acid multiple dose. Infection. 1990;18(Suppl 2):S89\u201393.","journal-title":"Infection"},{"issue":"Suppl 2","key":"92_CR56","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1007\/BF01643435","volume":"18","author":"H Thoumsin","year":"1990","unstructured":"Thoumsin H, Aghayan M, Lambotte R. Single dose fosfomycin trometamol versus multiple dose nitrofurantoin in pregnant women with bacteriuria: preliminary results. Infection. 1990;18(Suppl 2):S94\u20137.","journal-title":"Infection"},{"issue":"6","key":"92_CR57","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.acuro.2014.01.002","volume":"38","author":"F Lista","year":"2014","unstructured":"Lista F, Redondo C, Meilan E, Garcia-Tello A, Ramon de Fata F, Angulo JC. Efficacy and safety of fosfomycin-trometamol in the prophylaxis for transrectal prostate biopsy. Prospective randomized comparison with ciprofloxacin. Actas Urol Esp. 2014;38(6):391\u20136.","journal-title":"Actas Urol Esp"},{"issue":"Suppl 1","key":"92_CR58","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000472877","volume":"13","author":"P Periti","year":"1987","unstructured":"Periti P, Novelli A, Reali EF, Lamanna S, Fontana P. Prophylactic chemotherapy with fosfomycin trometamol salt during transurethral prostatic surgery: a controlled multicenter clinical trial. Eur Urol. 1987;13(Suppl 1):122\u201331.","journal-title":"Eur Urol"},{"issue":"11","key":"92_CR59","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/S0149-2918(00)86734-X","volume":"21","author":"GE Stein","year":"1999","unstructured":"Stein GE. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. Clin Ther. 1999;21(11):1864\u201372.","journal-title":"Clin Ther"},{"issue":"Suppl 2","key":"92_CR60","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1007\/BF01643436","volume":"18","author":"F Silverio di","year":"1990","unstructured":"di Silverio F, Ferrone G, Carati L. Prophylactic chemotherapy with fosfomycin trometamol during transurethral surgery and urological manoeuvres. Results of a multicentre study. Infection. 1990;18(Suppl 2):S98\u2013102.","journal-title":"Infection."},{"issue":"9","key":"92_CR61","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/jac\/dkq237","volume":"65","author":"ME Falagas","year":"2010","unstructured":"Falagas ME, Vouloumanou EK, Togias AG, et al. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2010;65(9):1862\u201377.","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 1","key":"92_CR62","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000222054","volume":"23","author":"R Fujii","year":"1977","unstructured":"Fujii R. Fosfomycin in the treatment of bacterial infections: summary of clinical trials in Japan. Chemotherapy. 1977;23(Suppl 1):234\u201346.","journal-title":"Chemotherapy."},{"issue":"2","key":"92_CR63","first-page":"77","volume":"31","author":"T Mayama","year":"1993","unstructured":"Mayama T, Yokota M, Shimatani I, Ohyagi H. Analysis of oral fosfomycin calcium (Fosmicin) side-effects after marketing. Int J Clin Pharmacol Ther Toxicol. 1993;31(2):77\u201382.","journal-title":"Int J Clin Pharmacol Ther Toxicol."},{"issue":"5","key":"92_CR64","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/003655401750174200","volume":"33","author":"S Durupt","year":"2001","unstructured":"Durupt S, Josserand RN, Sibille M, Durieu I. Acute, recurrent fosfomycin-induced liver toxicity in an adult patient with cystic fibrosis. Scand J Infect Dis. 2001;33(5):391\u20132.","journal-title":"Scand J Infect Dis"},{"issue":"3","key":"92_CR65","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1751-2980.2009.00385.x","volume":"10","author":"YP Wang","year":"2009","unstructured":"Wang YP, Shi B, Chen YX, Xu J, Jiang CF, Xie WF. Drug-induced liver disease: an 8-year study of patients from one gastroenterological department. J Dig Dis. 2009;10(3):195\u2013200.","journal-title":"J Dig Dis."},{"issue":"3","key":"92_CR66","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.anai.2010.07.004","volume":"105","author":"L Sanchez-Morillas","year":"2010","unstructured":"Sanchez-Morillas L, Perez-Ezquerra PR, Reano-Martos M, Mayorga C, Laguna-Martinez JJ. Anaphylaxis induced by fosfomycin. Ann Allergy Asthma Immunol. 2010;105(3):241.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"92_CR67","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.anai.2010.12.017","volume":"106","author":"PM Gamboa","year":"2011","unstructured":"Gamboa PM, Antepara I, Jauregui I, Urrutia I, Sanz ML. Two patients with anaphylactic shock due to fosfomycin. Ann Allergy Asthma Immunol. 2011;106(3):260\u20131.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"9","key":"92_CR68","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1398-9995.1998.tb04002.x","volume":"53","author":"MJ Rosales","year":"1998","unstructured":"Rosales MJ, Vega F. Anaphylactic shock due to fosfomycin. Allergy. 1998;53(9):905\u20137.","journal-title":"Allergy"},{"issue":"1","key":"92_CR69","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1469-0691.2011.03636.x","volume":"18","author":"R Raz","year":"2012","unstructured":"Raz R. Fosfomycin: an old\u2013new antibiotic. Clin Microbiol Infect. 2012;18(1):4\u20137.","journal-title":"Clin Microbiol Infect"},{"key":"92_CR70","author":"I Canamares-Orbis","year":"2014","unstructured":"Canamares-Orbis I, Silva JT, Lopez-Medrano F, Aguado JM. Is high-dose intravenous fosfomycin safe for the treatment of patients prone to heart failure? Enferm Infecc Microbiol Clin. 2014;. doi: 10.1016\/j.eimc.2014.07.005 .","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"Suppl 1","key":"92_CR71","first-page":"19","volume":"36","author":"HC Neu","year":"1990","unstructured":"Neu HC. Fosfomycin trometamol versus amoxycillin\u2013single-dose multicenter study of urinary tract infections. Chemotherapy. 1990;36(Suppl 1):19\u201323.","journal-title":"Chemotherapy."}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-015-0092-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T06:59:36Z","timestamp":1567234776000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40121-015-0092-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,5]]},"references-count":71,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["92"],"URL":"https:\/\/doi.org\/10.1007\/s40121-015-0092-8","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,5]]}}}